[Consensus on treatment of multisystemic inflammatory syndrome associated with COVID-19].

Ensinck, Gabriela; Gregorio, Gabriela; Flores, Rosana M; Crowe, Cecilia I; Clerico Mosina, Paola; Curi, Claudia; Jorro Barón, Facundo; Kohn Loncarica, Guillermo; Grinenco, Sofía; Ríos, Cecilia; González, Claudia; Zaslavsky, Vanesa; Lillo, Leonardo De; Vainstein, Eduardo; Urrutia, Luis

The pandemic caused by the SARS-CoV-2 virus declared by the WHO in March 11th 2020, affects a small number of pediatric patients, who mostly present mild respiratory compromise and favorable evolution. However began to be observed in previously healthy children, an increase in cases defined as "Multisystemic Inflammatory Syndrome" (MIS-C) or "Kawasaki-like" post-COVID 19 (KLC) that evolve to shock and require hospitalization in the Pediatric Intensive Care Unit. MIS-C and KL-C are characterized by fever; signs of inflammation, gastrointestinal symptoms, and cardiovascular dysfunction, associated with sever forms of presentation with higher incidence of hypotension and/or shock. In the laboratory, markers of inflammation, hypercoagulability and myocardial damage are observed. Firstline drug treatment consists of intravenous immunoglobulin plus oral acetylsalicylic acid. A multidisciplinary approach is recommended for an accurate diagnosis and an early and effective treatment, in order to reduce morbidity and mortality.